This synergy is in excellent agreement with a previous study that described cancer cells with increased β-catenin levels, for instance as the consequence of GSK3 inhibition, to be particularly sensitive to inhibition of BCL-2 by the ABT-199 analogue navitoclax35. Here, BCL2 is linked to cancer.